Optimal Diuretic Therapies for Acute Heart Failure With Volume Overload

NCT06166654 · tracked via the Priya Life Science Denmark tracker

Sponsor

Johannes Grand

Phase

Phase 4

Started

2024-09-05

Last updated

2026-08-14

Condition(s) studied

Acute Heart Failure

Investigational drug(s) / intervention(s)

Acetazolamide →Metolazone 2.5 MG →Double-placebo

Acetazolamide: 1\. 500 mg IV bolus of acetazolamide at randomization (day 0) and repeated the next 3 mornings (day 1, day 2 and day 3). This arm will also receive a placebo- Metolazone tablet together with each acetazolamide-injection.

Metolazone 2.5 MG: 2\. 2.5 mg oral Metolazone at randomization (day 0) and repeated the next 3 mornings (day 1, day 2 and day 3). This arm will also receive a placebo- acetazolamide injection together with each metolazone-tablet.

Double-placebo: This arm will also receive both a placebo-acetazolamide injection together with a placebo-metolazone-tablet at randomization and repeated the next 3 mornings (day 1, day 2 and day 3).

Study summary

Aim to identify the best strategy for treating acute heart failure (AHF) with volume overload, particularly focusing on patients resistant to standard loop-diuretics. The trial is a double-blinded, randomized, controlled, multicenter study. Its primary objective is to compare the efficacy of loop-diuretics combined with either Metolazone or Acetazolamide, against loop-diuretics alone. The trial will also determine the optimal type of loop-diuretic to use.

Eligible participants include adults over 18 years hospitalized with AHF and volume overload, showing signs of congestion and at risk of diuretic resistance. Exclusions apply to those with acute coronary syndrome, low systolic blood pressure, prior renal therapy, or previous treatment with Acetazolamide or Metolazone.

The primary outcome is the number of days alive and out-of-hospital by day 30. Secondary outcomes include a composite clinical benefit at 30 days, Kansas City Cardiomyopathy Questionnaire (KCCQ) scores, and successful decongestion 72 hours post-inclusion.

The trial aims to enroll about 1,041,939 patients across three treatment arms over three years. The minimal important difference is set as a reduction in out-of-hospital days by at least two days, with an anticipated low dropout rate. The study's power is calculated to be 80% with an adjusted alpha level for comparing the three diuretic groups.

Eligibility

Sex

ALL

Min age

18 Years

Max age

—

Healthy volunteers

Inclusion Criteria: 1. Age ≥ 18 years 2. Acute hospital admission with a clinical diagnosis of acute heart failure with volume overload. 3. Display risk of diuretic resistance, characterized by: 1. Daily loop-diuretics administration for a minimum of 7 days before admission, or 2. Insufficient decongestion observed in the preceding 24 hours (weight reduction \<500g or negative fluid balance \<1L) despite being treated with high-dose IV loop diuretic (equivalent to ≥120 mg IV furosemide within 24 hours). 4. Clinical signs of congestion, indicated by one or more of the following: pitting peripheral edema, ascites, elevated jugular venous pressure, or radiological/ultrasonic evidence of pulmonary congestion. Exclusion Criteria: 1. Acute coronary syndrome 2. Systolic blood pressure \<85 mmHg 3. Use of renal replacement therapy or ultrafiltration in-hospital before study inclusion 4. Treatment with acetazolamide or metolazone during the index hospitalization prior to randomization 5. Known allergy to any of the used drugs 6. Severe hypokalemia (\<2.5 mmol/l) or severe hyponatremia (\<125 mmol/l) 7. Severe hepatic impairment or liver cirrhosis 8. Known pregnancy

Primary outcome measure(s)

Days alive out-of-hospital to day 30 — 30 days
Days alive out-of-hospital to day 30

Trial sites (5)

Facility	City	Region	Status
Amager-Hvidovre Hospital	Hvidovre	Capital Region of Denmark	Recruiting
Aarhus university Hospital	Aarhus	Denmark	Recruiting
Bispebjerg Hospital	Copenhagen	Denmark	Not Yet Recruiting
Herlev-Gentofte hospital	Copenhagen	Denmark	Recruiting
Zealand University Hospital	Roskilde	Denmark	Recruiting

Other trials for the same condition

Infusion of Furosemide to Improve Diuretic Efficiency in Acute Heart Failure Recruiting

DECONGEST-AHF: Vasodilatation or Loop Diuretics in Acute Heart Failure Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06166654 on ClinicalTrials.gov ↗ ← All trials in Denmark